Literature DB >> 6106456

Duration of action and plasma levels of beta-adrenoceptor blocking drugs.

W H Aellig.   

Abstract

Since beta-adrenoceptor blocking drugs exhibit a long duration of action "despite" an elimination half-life of usually between 2 and 6 hours, it has been postulated that no direct correlation could exist between the time course of plasma levels and that of pharmacodynamic effects. Results of a study are reported in which 20 mg pindolol were administered orally to 8 healthy volunteers. Exercise tests were carried out and pindolol levels determined at various times for up to 24 hours after drug administration. A linear fall of the pharmacological effect (reduction of exercise-induced tachycardia) and an exponential fall of pindolol plasma levels were observed, indicating a linear relationship between the reduction of exercise-induced tachycardia and the logarithm of plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106456

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

1.  Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.

Authors:  J Drewe; R Meier; U Timonen; M Thumshirn; J Munzer; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.

Authors:  W H Aellig; E Nüesch; G Engel; J Grevel; W Niederberger; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

Review 3.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Contrasts between pindolol and propranolol concentration-response relationships.

Authors:  S G Carruthers; W L Pacha; W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.